NCT06906471PHASE1, PHASE2Recruiting

A Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS

Antelope Surgical Solutions, Inc

Start Date

7/1/2026

Completion Date

12/30/2026

Summary

A Single-Arm, blinded, fluorescent PSMA histopathology trial of AS1986NS

Eligibility Criteria

Age Range: 18 years to 90 years

Inclusion Criteria: * suspected prostate cancer warranting standard of care multi-core prostate biopsy Exclusion Criteria: * Patients receiving same-day therapeutic Lutetium-177 or Actinium-225 PSMA receptor radiation isotope therapy treatment * Patients with pre-existing, impaired or abnormal hepatic function, renal function, cardiac function, and abnormal elevated temperature * Patients with a creatinine clearance cutoﬀ (CrCl) of \< 60 mL/min

Interventions

DRUG

AS1986NS

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Prostate CancerProstate Cancer (Adenocarcinoma)Fluorescence Imaging

Locations

HCA Florida Kendall Hospital

Miami, Florida 33175

United States

Icahn School of Medicine at Mount Sinai (ISMMS)

New York, New York 10029

United States

Run studies, or work at a research site?

Corterve helps sites and sponsors reach patients who are looking for trials. It does not determine eligibility and does not promise an enrolment outcome.

For sponsors, CROs and sites

What Corterve sells to organisations, and the anti-kickback constraints it works within.

Services and published prices

Lay summaries for EU CTR Annex V, pre-screen filtration, recruitment-creative regulatory operations, feasibility reporting.

For research sites

One published licence rate, the same for every site, and the fees a site is never charged.